The 52-week efficacy and safety of adalimumab, a fully human monoclonal antibody that targets TNFα, in Western patients with moderately to severely active, treatment-refractory ulcerative colitis were demonstrated in the phase 3 studies ULTRA 1 and ULTRA 2 [13–16]. The gene discussed is TNF; the disease is ulcerative colitis.